A Randomized Study Comparing the Effects of PF708 and Forteo in Patients With Osteoporosis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Teriparatide (Primary)
- Indications Osteoporosis
- Focus Pharmacodynamics; Registrational
- Sponsors Pfenex
- 09 Nov 2017 According to a Pfenex media release, the company has announced interim PK data from this trial. These results were presented in the financial report.
- 22 Aug 2017 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018.
- 22 Aug 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2018.